October 4, 2019 – Results of a new economic analysis of the COAPT Trial data found that transcatheter mitral valve replacement (TMVR) combined with guideline-directed medical therapy (GDMT) is a...
Heart Failure
This heart failure channel offers news and new technology to treat heart failure. This includes for new innovations to treat congesitive heart failure (CHF). The channel includes news on HFpEF and HFrEF.
-
-
October 3, 2019 – The three-year results from the ...
-
-
The U.S. Food and Drug Administration (FDA) approved the Barostim Neo System for the improvement of symptoms in patients with advanced heart failure who are not suited for treatment with other...
News | Heart Failure | October 16, 2019
October 16, 2019 — Researchers have shown for the first time in preclinical studies that the...
The COAPT Economic Analysis sub-study found it is cost effective to treat heart failure patients who have severe secondary mitral regurgitation with MitraClip to reduce their MR symptoms.
News | Heart Failure | October 04, 2019
October 4, 2019 – Results of a new economic analysis of the COAPT Trial data found that transcatheter mitral valve...
COAPT Trial three-year data show the MitraClip continues to show safety and effectiveness in heart failure patients with secondary mitral reguritation.
News | Heart Failure | October 03, 2019
October 3, 2019 – The three-year results from the...
A MitraClip case underway at the University of Colorado Hospital hybrid cath lab. Left to right are doctors John Carroll, Edward Gill and Dominik Wiktor.
Blog | University of Colorado Hospital | October 02, 2019
In late December 2018, I had the opportunity to conduct an onsite visit to the...
News | Heart Failure | September 27, 2019
September 27, 2019 — Ancora Heart Inc. announced results from an interim analysis of...
News | Heart Failure | September 20, 2019
September 20, 2019 — The new Max and Debra Ernst Heart Center at Beaumont Hospital, Royal Oak, Mich., will open Sept...
News | Heart Failure | September 18, 2019
September 18, 2019 — AstraZeneca announced the U.S. Food and Drug Administration (FDA) has granted Fast Track...
The REDUCE LAP HF-II study will combine Corvia Medical's InterAtrial Shunt Device (IASD), pictured here, with physIQ's continuous monitoring platform to evaluate the device's efficacy in patients with heart failure. Image courtesy of Corvia Medical.
News | Heart Failure | September 12, 2019
September 12, 2019 — Corvia Medical has sponsored and is actively enrolling patients in a...
News | Heart Valve Technology | September 11, 2019
September 11, 2019 — Percutaneous reduction of...
Image courtesy of Amazon.com
News | Heart Failure | September 11, 2019
September 11, 2019 — The ever-present devices that seem to track all our moves can be annoying, intrusive or worse,...
News | Heart Failure | September 09, 2019
September 9, 2019 — AstraZeneca announced detailed results from the landmark Phase III DAPA-HF...
News | Heart Failure | September 09, 2019
September 9, 2019 — The drug Dapagliflozin was found to reduce death and hospitalization in patients who have heart...
News | Heart Failure | September 04, 2019
September 4, 2019 – Novartis announced results from two new...
